72 citations,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
October 2023 in “The Journal of urology/The journal of urology” Higher testosterone and DHT levels are not linked to urinary symptoms in men.
403 citations,
November 2005 in “Journal of Endocrinology” Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
17 citations,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
September 2010 in “European Urology Supplements” Serum triglyceride levels are not linked to prostate cancer risk.
9 citations,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
29 citations,
March 2021 in “Frontiers in Endocrinology” Testosterone may influence COVID-19 severity and outcomes.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
January 2025 in “HORMONES” Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.
1 citations,
August 2013 in “Journal of the National Cancer Institute” Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.